NASDAQ:ACHN - Achillion Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$2.93 -0.01 (-0.34 %)
(As of 04/22/2019 02:00 AM ET)
Previous Close$2.93
Today's Range$2.82 - $2.97
52-Week Range$1.29 - $3.98
Volume1.08 million shs
Average Volume1.58 million shs
Market Capitalization$406.45 million
P/E RatioN/A
Dividend YieldN/A
Beta2.47
Achillion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis. The company is also developing ACH-5228, a factor D inhibitor that is in Phase I clinical trials; and ACH-5548, a factor D inhibitor, which is in Phase I clinical trials for the treatment of PNH and other complement mediated diseases. It has license agreements with Ora, Inc. for the development and commercialization of ACH-702; and GCA Therapeutics, Ltd for elvucitabine, a nucleoside reverse transcriptase inhibitor for the treatment of hepatitis B infection and human immunodeficiency virus infection. The company was founded in 1998 and is based in New Haven, Connecticut.

Receive ACHN News and Ratings via Email

Sign-up to receive the latest news and ratings for ACHN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ACHN
CUSIP00448Q20
Phone203-624-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$15 million
Book Value$1.92 per share

Profitability

Net Income$-70,270,000.00

Miscellaneous

Employees56
Market Cap$406.45 million
Next Earnings Date5/1/2019 (Estimated)
OptionableOptionable

Achillion Pharmaceuticals (NASDAQ:ACHN) Frequently Asked Questions

What is Achillion Pharmaceuticals' stock symbol?

Achillion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACHN."

How were Achillion Pharmaceuticals' earnings last quarter?

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) announced its earnings results on Thursday, March, 7th. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, beating analysts' consensus estimates of ($0.15) by $0.03. View Achillion Pharmaceuticals' Earnings History.

When is Achillion Pharmaceuticals' next earnings date?

Achillion Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, May 1st 2019. View Earnings Estimates for Achillion Pharmaceuticals.

What price target have analysts set for ACHN?

2 equities research analysts have issued 12-month price targets for Achillion Pharmaceuticals' stock. Their forecasts range from $5.00 to $5.00. On average, they anticipate Achillion Pharmaceuticals' stock price to reach $5.00 in the next year. This suggests a possible upside of 70.6% from the stock's current price. View Analyst Price Targets for Achillion Pharmaceuticals.

What is the consensus analysts' recommendation for Achillion Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Achillion Pharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Achillion Pharmaceuticals.

Has Achillion Pharmaceuticals been receiving favorable news coverage?

News stories about ACHN stock have been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Achillion Pharmaceuticals earned a news impact score of 1.2 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future.

Are investors shorting Achillion Pharmaceuticals?

Achillion Pharmaceuticals saw a decline in short interest in the month of March. As of March 15th, there was short interest totalling 12,379,720 shares, a decline of 15.2% from the February 28th total of 14,591,293 shares. Based on an average daily volume of 2,086,359 shares, the short-interest ratio is currently 5.9 days. Approximately 9.2% of the company's stock are short sold. View Achillion Pharmaceuticals' Current Options Chain.

Who are some of Achillion Pharmaceuticals' key competitors?

What other stocks do shareholders of Achillion Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Achillion Pharmaceuticals investors own include Chesapeake Energy (CHK), Skyworks Solutions (SWKS), Madrigal Pharmaceuticals (MDGL), Noble (NE), Gilead Sciences (GILD), Eiger Biopharmaceuticals (EIGR), Celldex Therapeutics (CLDX), Iconix Brand Group (ICON), ACADIA Pharmaceuticals (ACAD) and Edap Tms (EDAP).

Who are Achillion Pharmaceuticals' key executives?

Achillion Pharmaceuticals' management team includes the folowing people:
  • Mr. Joseph Truitt, Pres, CEO & Director (Age 54)
  • Ms. Martha E. Manning, Exec. VP, Gen. Counsel & Corp. Sec. (Age 64)
  • Mr. Brian R. Di Donato, CFO, SVP & Treasurer (Age 52)
  • Mr. Paul Firuta, Exec. VP & COO (Age 53)
  • Dr. Kevin P. Malobisky, Sr. VP of Regulatory Affairs, Quality & Compliance

Who are Achillion Pharmaceuticals' major shareholders?

Achillion Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Rhenman & Partners Asset Management AB (0.20%) and Virtu Financial LLC (0.01%). View Institutional Ownership Trends for Achillion Pharmaceuticals.

Which major investors are selling Achillion Pharmaceuticals stock?

ACHN stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB. View Insider Buying and Selling for Achillion Pharmaceuticals.

Which major investors are buying Achillion Pharmaceuticals stock?

ACHN stock was purchased by a variety of institutional investors in the last quarter, including Virtu Financial LLC. View Insider Buying and Selling for Achillion Pharmaceuticals.

How do I buy shares of Achillion Pharmaceuticals?

Shares of ACHN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Achillion Pharmaceuticals' stock price today?

One share of ACHN stock can currently be purchased for approximately $2.93.

How big of a company is Achillion Pharmaceuticals?

Achillion Pharmaceuticals has a market capitalization of $406.45 million and generates $15 million in revenue each year. The biopharmaceutical company earns $-70,270,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis. Achillion Pharmaceuticals employs 56 workers across the globe.

What is Achillion Pharmaceuticals' official website?

The official website for Achillion Pharmaceuticals is http://www.achillion.com.

How can I contact Achillion Pharmaceuticals?

Achillion Pharmaceuticals' mailing address is 300 GEORGE STREET, NEW HAVEN CT, 06511. The biopharmaceutical company can be reached via phone at 203-624-7000.


MarketBeat Community Rating for Achillion Pharmaceuticals (NASDAQ ACHN)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  454 (Vote Outperform)
Underperform Votes:  367 (Vote Underperform)
Total Votes:  821
MarketBeat's community ratings are surveys of what our community members think about Achillion Pharmaceuticals and other stocks. Vote "Outperform" if you believe ACHN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACHN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel